Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedNA
-/- inconclusive
    ConPlas-19, 2020
     
    NCT04345523
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    38/43 inconclusive
      Gharbharan et al., 2020
       
      NCT04342182
      RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
      43/43 inconclusive
      • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      Abolghasemi, 2020
       
      IRCT20200325046860N1
      OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
      115/74 inconclusive

        COVID-19 mild to moderate meta-analysis

        Libster, 2020
         
        NCT04479163
        RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
        80/80 conclusif
        • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
        PLACID, 2020
         
        CTRI/2020/04/024775
        RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
        235/229 suggested
        • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
        • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias

        COVID-19 severe or critically meta-analysis

        AlQahtani, 2020
         
        NCT04356534
        RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
        20/20 inconclusive
        • inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
        Bajpai M, 2020
         
        NCT04346446
        RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
        14/15 inconclusive
        • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
        PlasmAr, 2020
         
        NCT04344535
        RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
        228/105 inconclusive
        • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
        PlasmAr, 2020
         
        NCT04344535
        RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
        228/105 inconclusive
        • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
        Ray, 2020
         
        CTRI/2020/05/025209
        RCTconvalescent plasma treatmentcontrolCOVID-19 severe or critically
        bias due to deviations from intended interventions some concern
        bias due to missing outcome data low
        bias in measurement of the primary outcome low
        bias in selection of the reported result high
        " >high
        40/40 inconclusive Li, 2015
         
        ChiCTR2000029757 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
        52/51 inconclusive Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        10/10 inconclusive Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        20/20 inconclusive Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        21/28 inconclusive Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        39/156 inconclusive

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).